Phase I clinical trials in 56 patients with thyroid cancer: The M. D. Anderson Cancer Center experience

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 11, 2009, Pages 4423-4432

  Tsimberidou, Apostolia Maria ^a   Vaklavas, Christos ^b   Wen, Sijin ^a   Hong, David ^a   Wheler, Jennifer ^a   Ng, Chaan ^a   Naing, Aung ^a   Tse, Susan ^a   Busaidy, Naifa ^a   Markman, Maurie ^a   Sherman, Steven I ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; AXITINIB; AZACITIDINE; CYTOTOXIC AGENT; EPOTHILONE B; GEFITINIB; IMATINIB; MK 2461; MOTESANIB; RADIOACTIVE IODINE; RTA 402; SORAFENIB; TIPIFARNIB; UNCLASSIFIED DRUG; VALPROIC ACID; VANDETANIB; VORINOSTAT; XL 184;

ADULT; AGED; ANAPLASTIC THYROID CARCINOMA; ARTICLE; CANCER CENTER; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; FOLLICULAR THYROID CARCINOMA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUTROPENIA; PAPILLARY THYROID CARCINOMA; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SKIN DEFECT; SURVIVAL RATE; THROMBOSIS; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TREATMENT FAILURE; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

EID: 70449090354     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0743     Document Type: Article

References (37)

1. Nikiforov YE 2008 Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21(Suppl 2):S37-S43 (Pubitemid 351592770)
2. Surveillance Epidemiology and End Results Program of the National Cancer Institute. http://seer.cancer.gov/statfacts/html/thyro.html
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ 2008 Cancer statistics, 2008. CA Cancer J Clin 58:71-96
4. Sherman S, Gillenwater AM 2003 Cancer medicine 6. 6th ed. Hamilton, Ontario, Canada: BC Becker Inc.
5. Tuttle RM, Leboeuf R 2007 Investigational therapies for metastatic thyroid carcinoma. J Natl Compr Canc Netw 5:641-646 (Pubitemid 47057053)
6. Baudin E, Schlumberger M 2007 New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 8:148-156 (Pubitemid 46158381)
7. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M 2008 New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:22-32 (Pubitemid 350291115)
8. Neff RL, Farrar WB, Kloos RT, Burman KD 2008 Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 37:525-538, xi
9. Taccaliti A, Boscaro M 2009 Genetic mutations in thyroid carcinoma. Minerva Endocrinol 34:11-28
10. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M 2006 Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91:3667-3670 (Pubitemid 44402153)
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
12. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ 2006 Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512 (Pubitemid 46630627)
13. Cancer Therapy Evaluation Program of the National Cancer Institute. http://ctep.cancer.gov/
14. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
15. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
16. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl JM359:31-42 (Pubitemid 351931094)
17. Gottlieb JA, Hill Jr CS 1974 Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 290:193-197
18. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155-2160 (Pubitemid 16236586)
19. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat P, Fiorentino MV 1991 Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14:475-480
20. Nemunaitis JJ, Senzer NN, Kurzrock R, Ng CS, Das A, Atienza RS, Zang EA, Jansen M, Ashworth S, Hong DS 2008 Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 26 (Abstract 14583, p. 634s)
21. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
22. Ain KB, Lee C, Williams KD 2007 Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 17:663-670 (Pubitemid 47311556)
23. Iten F, Müller B, Schindler C, Rochlitz C, Oertli D, Mäcke HR, Muller-Brand J, Walter MA 2007 Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 13:6696-6702
24. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS 2007 Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:2369-2376 (Pubitemid 46999207)
25. Haddad RI, Krebs AD, Vasselli J, Paz-Ares LG, Robinson B 2008 A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 26:6024 (Abstract, p. 322s)
26. Goulart B, Carr L, Martins RG, Eaton K, Kell E, Wallace S, Capell P, Mankoff D 2008 Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC). J Clin Oncol 26(Suppl); Abstract 6062, p. 331s
27. Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R 2008 Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 7:1001-1006
28. Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, Ratain MJ, Kuzrock R 2008 A phase I study of XL184, a RET, VEGFR2, and METkinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 26(Suppl): Abstract 3522, p. 158s
29. Chintala L, Kurzrock R, Fu S, Naing A, Wheler JJ, Moulder SL, Newman R, Gagel R, Sebti S, Wright JJ, Hong DS 2008 Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156). 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 26(Suppl): Abstract 3593, p. 176s
30. Hong DS, Kurzrock R, Supko JG, Lawrence DP, Wheler JJ, Meyer CJ, Mier JW, Andreeff M, Shapiro GI, Dezube BJ 2008 Phase I trial with a novel oral NF-κB/STAT3 inhibitor RTA 402 in patients with solid tumors and lymphoid malignancies. J Clin Oncol 26(Suppl): Abstract 3517, p. 157s
31. Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kuzrock R 2008 Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 14:6296-6301
32. Kurzrock R 2007 Evaluate the effects of patupilone on the pharmacokinetics of midazolam and omeprazole in patients with advanced malignancies. http://clinicaltrialsgov/ct2/show/NCT00420615
33. Camacho LH, Moulder SL, LoRusso PM, Blumenschein GR, Bristow PJ, Kurzrock R, Fu S, Schlienger K, Bergstrom DA 2008 First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors. J Clin Oncol 26:(Suppl): Abstract 14657, p. 639s
34. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE 2007 A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:3466-3469 (Pubitemid 47435321)
35. Wells Jr SA, Gosnell JE, Gagel RF, Moley JF, Pfister DG, Sosa JA, Skinner M, Krebs A, Hou J, Schlumberger M 2007 Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 25(Suppl): Abstract 6018, p. 303e
36. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ 2008 A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18:317-323
37. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M, Shah MH 2009 Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 94:164-170